RxDoctor Payments Data

Emily Battle, MD

Gastroenterology · South Charleston, WVNPI 1124114269

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.9% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 35.1% of the total. Reporting peaked in 2019 at $253 and has fallen 79.0% since, to $53 in 2025. That places this record below the midpoint for gastroenterology clinicians in WV, where the typical reported total is $1,371.

$739in general payments, 2019–2025

Across 42 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$259
  • Pfizer$129
  • Takeda Pharmaceuticals U.S.A., Inc.$124
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$78
  • QOL Medical, LLC$35
  • Ironwood Pharmaceuticals, Inc$33
  • plus $81 from 4 others

What the payments were for

  • Food & beverage$70996%
  • Education$304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$739 in reported general payments places this provider in the 30th percentile of 72 gastroenterology providers in West Virginia.

See all gastroenterology providers in West Virginia

Medicare billing

Part B allowed, 2024
$68,116
Medicare patients
341
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$313,583
EntyvioVedolizumab11$98,170
LinzessLinaclotide25$28,786
Mesalamine ErMesalamine24$16,801
Colestipol Hcl31$3,821
Famotidine132$1,778
Omeprazole130$1,578
Magnesium Sulfate48$1,463
Pantoprazole Sodium115$1,389
Sodium Chloride0.9 % Sodium Chloride59$793
Budesonide EcBudesonide13$630
Dicyclomine Hcl37$579
Esomeprazole Magnesium15$367
Lansoprazole11$289
Metronidazole15$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$124$98,17011 claims
AbbVieLinzess$259$28,78625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 72 gastroenterology providers in West Virginia.

Other gastroenterology in South Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →